Compare CIVB & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CIVB | YDES |
|---|---|---|
| Founded | 1884 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.6M | 476.8M |
| IPO Year | 2012 | 2024 |
| Metric | CIVB | YDES |
|---|---|---|
| Price | $28.21 | $4.77 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $30.92 | N/A |
| AVG Volume (30 Days) | 103.5K | ★ 361.4K |
| Earning Date | 10-22-2026 | 08-31-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 31.34 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $19,023,000.00 | N/A |
| Revenue This Year | $10.45 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | $19.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.10 | $1.70 |
| 52 Week High | $29.97 | $17.99 |
| Indicator | CIVB | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 44.05 |
| Support Level | $27.97 | $2.33 |
| Resistance Level | $29.31 | $5.15 |
| Average True Range (ATR) | 0.57 | 0.98 |
| MACD | 0.19 | -0.31 |
| Stochastic Oscillator | 83.07 | 21.54 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.